You are here

Study Evaluating Renal Cell Carcinoma Risk Factors

Last updated on November 10, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Pamplona, Navarra, 31008 Spain
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery
or radiotherapy)

- =18 years, any gender.

- Patients with advanced Renal Cell Carcinoma and treatment naïve.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who have already initiated any kind of specific therapy for the treatment of
RCC.2.

- Patients with other neoplasias different from RCC (current or past).

NCT00927043
Pfizer
Completed
Study Evaluating Renal Cell Carcinoma Risk Factors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer
NCT04152018
All Genders
18+
Years
San Antonio, Texas
Descriptive Information
Brief TitleStudy Evaluating Renal Cell Carcinoma Risk Factors
Official TitleProspective, Multicenter, Epidemiological Study To Determine The Clinical, Molecular And Genetic Factors Associated To The Prognosis Of Patients With Advanced Renal Cell Carcinoma
Brief SummaryThis is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell carcinoma (RCC) treatment.
Detailed Descriptioninvitation to volunteer
Study TypeObservational
Study DesignObservational Model: Cohort
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenRetention:   Samples With DNA
Description:
Whole blood
Sampling MethodNon-Probability Sample
Study PopulationTreatment naive patients with proven advanced RCC
ConditionCarcinoma, Renal Cell
InterventionOther: Epidemiological study according to clinical practice
Epidemiological study according to clinical practice.
Study Groups/Cohorts1
Intervention: Other: Epidemiological study according to clinical practice
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: November 4, 2011)
145
Original Estimated Enrollment
 (submitted: June 23, 2009)
122
Actual Study Completion DateSeptember 2011
Actual Primary Completion DateSeptember 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery or radiotherapy)
  • =18 years, any gender.
  • Patients with advanced Renal Cell Carcinoma and treatment naïve.

Exclusion Criteria:

  • Patients who have already initiated any kind of specific therapy for the treatment of RCC.2.
  • Patients with other neoplasias different from RCC (current or past).
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesSpain
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00927043
Other Study ID Numbers3066K1-4433
B1771010
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyPfizer
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateNovember 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now